Merck KGaA licensed access to BioWa’s Potelligent® Technology for the research, development, and commercialization of its antibody therapies. Under this nonexclusive agreement, BioWa received up-front fees and may earn development milestone payments and royalties.


Potelligent is designed to improve potency and efficacy of antibody therapeutics by enhancing antibody-dependent cellular cytotoxicity. It involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell.

Previous articlePotential Effects of Pending Biologics Legislation on the Patent Application Process
Next articleGW Pharmaceuticals’ Plant for MS and Cancer Pain Drug Gets U.K. GMP Clearance